Table 5.

Adjusted RRs of developing ER+PR+, ER+PR, and ERPR breast cancers in relation to hormone levels in postmenopausal women of the ORDET cohort

Total testosterone (median nmol/L)ER+PR+
ER+PR
ERPR
Cases/controlsRR* (95% CI)Cases/controlsRR* (95% CI)Cases/controlsRR* (95% CI)
    1 (0.56)20/2311.008/2311.007/2311.00
    2 (0.87)30/2001.76 (0.97-3.21)8/2001.11 (0.41-3.04)6/2001.01 (0.33-3.08)
    3 (1.25)39/1932.33 (1.31-4.15)20/1933.06 (1.31-7.16)10/1931.80 (0.67-4.84)
    P for trend0.0050.0050.227
    Continuous1.53 (1.20-1.95)1.76 (1.23-2.50)1.16 (0.75-1.80)
    P heterogeneity§0.770.35
Free testosterone (median pmol/L)
    1 (0.80)22/2081.0012/2081.004/2081.00
    2 (1.67)27/2081.24 (0.68-2.26)9/2080.71 (0.29-1.73)9/2082.30 (0.70-7.61)
    3 (3.28)40/2081.79 (1.02-3.14)15/2081.20 (0.54-2.64)10/2082.59 (0.80-8.43)
    P for trend0.0330.4950.153
    Continuous1.36 (1.08-1.73)1.13 (0.80-1.59)1.33 (0.86-2.05)
    P heterogeneity§0.790.49
Estradiol (median pmol/L)
    1 (10.1)22/2081.0016/2081.008/2081.00
    2 (19.3)33/2081.51 (0.85-2.69)7/2080.45 (0.18-1.12)6/2080.76 (0.26-2.24)
    3 (32.5)34/2081.54 (0.87-2.74)13/2080.82 (0.38-1.76)9/2081.10 (0.41-2.91)
    P for trend0.1790.6900.793
    Continuous1.26 (0.97-1.64)0.92 (0.69-1.23)0.90 (0.63-1.28)
    P heterogeneity§0.680.64
SHBG (median nmol/L)
    1 (54.9)28/2081.0012/2081.0010/2081.00
    2 (91.6)34/2091.17 (0.68-2.01)13/2091.08 (0.48-2.43)6/2090.56 (0.20-1.59)
    3 (141.0)27/2070.98 (0.56-1.72)11/2070.97 (0.41-2.25)7/2070.67 (0.25-1.81)
    P for trend0.8920.4670.451
    Continuous0.80 (0.55-1.18)1.00 (0.71-1.40)0.80 (0.55-1.18)
    P heterogeneity§0.530.59
  • * Adjusted for age, age at first birth, and family history of breast cancer.

  • P value for trend from model with the median of tertiles entered as continuous variable.

  • Log transformed.

  • § Wald test for heterogeneity.